Market Overview

Genomic editing refers to the strategies and techniques implemented for modifying any living organism's target genetic information. Genome editing includes gene alteration by recombinant technology in different locations, which improves insertion precision and decreases cell toxicity.

The genome editing industry is still in the developing phase and will witness numerous growth opportunities in forthcoming years as the key industry players will introduce new technologies.

The global genome editing market was valued at USD 3,933.07 million in 2019 and is expected to grow at 14.5% CAGR during the forecast study period.

Impact of COVID-19

During this COVID-19 pandemic, market players are striving to offer reagents to clinicians and researchers working on understanding COVID-19 and developing cures for the disease. Genomics products are a critical tool for infectious disease research because they provide a detailed understanding of how the virus infected people, how the immune system is mobilized, which immune cells react to pathogens, and several other aspects of the disease and potential therapies. Genomic data is essential to develop tests, find drugs and vaccines. It is also of utmost importance to find if there has been a mutation of the virus.. All these applications associated with genomics will drive the market growth during the COVID-19 pandemic situation.

Extensive Application Area of Genomic

Genomics finds applications across agriculture, veterinary sciences, and forensics and has developed significantly in recent years among other fields. Since the emergence of next-generation sequencing, the use of genomics in forensic research has increased considerably. This is because NGS enables more information from a trace or damaged DNA sample to be analyzed at-scene and extracted.

Next-generation plant breeding technologies are used to produce improved plant varieties. Breeders can sequence critical traits by genome sequencing and can generate crop varieties capable of producing more yield. Besides, NSG can be used for barcoding DNA to classify fish larvae and eggs, along with a broad overview of fish species, during the fish population assessment. In the same way, genomics is being widely used in food quality and health research as food product genomic testing can efficiently detect micro-organisms that are present in those products. Considering the promising potential of genomics in the food industry, market players are concentrating on introducing dedicated food quality and safety test products and services. For example, Neogen (the U.S.) announced NGS services for the food industry in June 2017, enabling food companies to test and classify all bacteria in a sample using a single genomic test.

Increasing Research Funding for Gnenome Application

The data obtained from genetic testing can be used in the gene-editing process that is proving beneficial for the development of the industry. Increasing pool of market innovators investing significant revenue share on R&D in genome applications is anticipated to drive the global genomics market during the forecast period. The increasing demand for creating and upgrading genome databases and the rising adoption of single cell-based genomic analysis is expected to boost the growth of the genomics market

Gene editing includes the use of mutated genes for multiple applications in industry and agriculture. For example, the technique of gene editing is used in the development of organically engineered crops to increase yield. In addition, the government is funding various research activities related to the treatment of different diseases that will propel the market. Numerous public and private sector organizations across the world, on the other hand, are investing in creating and upgrading genomic repositories. For instance, in October 2019, the Department of Biotechnology under the Government of India launched the Genome India project. The project aimed at cataloging of genomic data of 100,000 Indians. Governments in developed countries like the U.S., the U.K., Canada, and Japan are also upgrading their existing genomic databases

Segmental Overview

Ease of Use and Excellent Target Precision Makes CRISPR the Leading Segment

The CRISPR segment holds the largest share, and the market is projected to dominate during the forecast period. Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR) has emerged as a crucial genome-editing technology. A significant benefit over ZFN and TALENs is — the ease of use associated with the CRISPR system. A CRISPR / Cas9 device has excellent target precision, so it does not require sophisticated enzyme engineering. The advantage of using technology is that it can be adapted to treat patient-specific mutations for diseases such as cystic fibrosis.

In addition, the increase in funding, government initiatives to improve vaccines, medical technology, medicines, and devices further accelerate the growth of the global genome editing industry. For example, IN May 2018, Feng Zhang 's Beam Therapeutics firm, a new start-up to develop CRISPR, has officially released USD 87 million in Series A funding and a mission to develop "precision genetic medicines" using CRISPR technology to edit just one nucleotide base, or "letter," in the genome at a time. Furthermore, in 2017, Synthego and Thermo Fisher Scientific join forces to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering.

Thermo Fisher Scientific is investing substantially in the development of its CRISPR technology to deliver better research efficiency and accuracy as well as meeting unmet research and therapeutic requirements. Cas9 protein and FokI protein were combined to form a dimeric CRISPR / Cas9 RNA-guided FokI nuclease system that is predicted to have a wide range of applications for genome editing

Pharmaceutical Companies Investing Substantially to Upgrade Gene-Editing Techniques  

Primary revenue size can be due to the increasing use of gene editing techniques in research activities conducted by pharmaceutical and biotechnology firms to produce and develop rare disease drugs. In addition, leading pharmaceutical firms are investing in R&D, which raises the preference for technologically advanced gene-editing techniques such as TALENS. Established firms like Thermo Fisher and Sigma Aldrich Corporation are engaged in the provision of custom vectors for cell line editing and engineering. In the near future, outsourcing of these services is estimated to rise and thus boost growth.

Regional Overview

U.S Houses Leading Market Players, thereby Driving the Regional Market Growth 

North America region has been a dominant region in the genome editing market owing to the higher adoption of advanced techniques in the research institutes based in the U.S, substantial investments in research by government organizations, development of gene therapy, increasing use of GM crops and advanced healthcare infrastructure. Favorable regulations for usage and reimbursement are expected to fuel the adoption of genetic tests in this region. Moreover, the strong presence of key players such as Bio-Rad Laboratories, Inc., Cepheid, Inc., Agilent Technologies, and Danaher Corporation have also contributed to the revenue generated by this region. Whereas companies such as Illumina, Genomic Health, and Bluebird Bio that is operating at the forefront for revolutionizing the genomics industry are also headquartered in the U.S. These companies serve as pioneers in the fields of genetic sequencing, genetic diagnostics, and gene therapy respectively.

Asia-Pacific’s Increasing Genomics Technology Adoption and Widespread Awareness Drives the Regional Market Growth

Asia-Pacific is expected to witness the fastest growth during the forecast period, owing to increasing adoption and awareness for the latest genomics technologies in the emerging countries of this region. These technologies have been adequately developed in order to detect, treat, and prognosis of genetic disorders. China is playing a vital role in the Asia-Pacific regional market growth by taking initiatives such as the introduction of the Precision Medicine Initiative (PMI) for the use of genomics in healthcare in 2017. Government-funded population-based genomics studies and foreign investments in Asia-pacific are contributing to market growth. For instance, Garvan Institute of Medical Research based in Australia has been funded by New South Wales (NSW) provincial government each year in order to progress the genomic research. Increased biotech and personalized medicine work in the Asia Pacific region's economies is projected to spur growth in the coming years. Additionally, a high preference for gene editing techniques for manufacturing BT (Biotechnologically engineered) crops will foster Indian gene editing industry growth in the coming years.

Competitive Landscape

The key players operating in the global genome editing market are Addgene, Allele Biotech, Bio-Rad Laboratories, Inc., Takara Bio Inc., CRISPR Therapeutics, Integrated DNA Technologies, OriGene Technologies, Precision Biosciences, GE Healthcare, GeneCopoeia, Inc., GenScript Corporation, Horizon Discovery Group plc, Merck Millipore Limited, Sangamo Biosciences, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific and Caribou Biosciences, Inc.

Recent Development

• In June 2019, BGI signed a partnership agreement with Eluthia, a Germany-based biotechnology company, for the development and commercialization of reproductive genetic tests across Germany. Such collaborations are set to intensify the market competition in the near future.
• In 2018, Inscripta Colorado-based biotech acquired Solana Biosciences to ramp up the commercialization of its gene-editing technology. This strategy aims to expand access to CRISPR by offering new enzymes free of charge, and also to bolster research on CRISPR by equipping scientists with a full suite of tools.

Genome Editing Market Segmentation

By Technology

• CRISPR
• TALEN
• ZFN

By Application

• Cell Line Engineering
• Animal Genetic Engineering
• Plant Genetic Engineering
• Other Applications

By End-User

• Pharmaceutical and Biotechnology Companies
• Academics and Government Research Institutes
• Contract Research Organizations
• Other End Users

By Regions

• North America
• Europe
• Asia-Pacific
• Central, South America, and the Caribbean
• The Middle East and Africa